|
Nov 6
|
Myriad Genetics Inc (MYGN) Reports 23% YoY Revenue Growth in Q3 2023
|
|
Nov 6
|
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
|
|
Nov 4
|
Insider Sell: CFO Richard Riggsbee Sells 30,000 Shares of Myriad Genetics Inc
|
|
Sep 12
|
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
|
|
Sep 8
|
Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
|
|
Sep 7
|
Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?
|
|
Sep 6
|
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
|
|
Sep 6
|
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
|
|
Aug 8
|
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
|
|
Aug 7
|
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
|
|
Aug 7
|
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
|
|
Aug 5
|
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Earnings Call Transcript
|
|
Aug 5
|
Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Aug 4
|
Q2 2023 Myriad Genetics Inc Earnings Call
|
|
Aug 3
|
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 3
|
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
|
|
Apr 26
|
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
|